AtriCure Inc
Closed
SectorHealthcare
54.5 2.87
Overview
Share price change
24h
Min
54.23
Max
54.78
Income | 8.8M 9M |
|---|---|
Sales | 12M 154M |
P/E Sector Avg | 245.333 56.597 |
EPS | 0.18 |
Profit margin | 5.83 |
Employees | 1,350 |
EBITDA | -3.8M 3.2M |
Next Earnings | 28 paź 2026 |
|---|
Market Cap | 860M 2.6B |
|---|---|
Previous open | 51.63 |
Previous close | 54.5 |
News Sentiment
By Acuity
67%
33%
291 / 339 Ranking in Healthcare
AtriCure Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
AtriCure Inc Forecast
Sentiment
By Acuity
291 / 339 Ranking in Healthcare
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About AtriCure Inc
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
